...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of diabetes investigation. >Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
【24h】

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study

机译：高剂量二甲双胍单药治疗或低剂量二甲双胍/利格列汀联合治疗在改善血糖控制不足的2型糖尿病患者中，尽管采用低剂量二甲双胍单药治疗，可改善血糖变异性？一项基于随机，交叉，连续血糖监测的先导研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims/Introduction The present study investigated the effect of high‐dose metformin or low‐dose metformin/linagliptin combination therapy on glycemic variability (GV) in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy in a cross‐over study using continuous glucose monitoring. Materials and Methods The present study was carried out with 11 type 2 diabetes outpatients (7% glycated hemoglobin 10%) receiving low‐dose metformin monotherapy (500–1,000 mg). All patients were assigned to either metformin 1,500 mg monotherapy (HMET) or combination therapy of low‐dose (750 mg) metformin and linagliptin 5 mg (LMET + dipeptidyl peptidase‐4 [DPP4]). GV was evaluated by continuous glucose monitoring after 4 weeks of the initial treatment and again after cross‐over to the other treatment. GV metrics were compared between the treatments using the Wilcoxon signed‐rank test. Results Of the continuous glucose monitoring‐derived GV metrics for the HMET versus LMET + DPP4, mean glucose levels, standard deviations and mean amplitude of glucose excursions were not significantly different. Although the pre‐breakfast glucose levels were not significantly different among the treatments ( P = 0.248), the 3‐h postprandial glucose area under the curve (160 mg/dL) after breakfast was significantly larger with HMET versus LMET + DPP4 (9,550 [2,075–11,395] vs 4,065 [1,950–8,895]; P = 0.041). Conclusions A comparison of GV with HMET versus LMET + DPP4 suggested that LMET + DPP4 might reduce post‐breakfast GV to a greater degree than HMET in type 2 diabetes patients receiving low‐dose metformin monotherapy.
机译：目的/简介本研究在交叉研究中调查了尽管血糖控制不足的二型糖尿病患者，但血糖控制不足的大剂量二甲双胍或小剂量二甲双胍/利拉列汀联合治疗对血糖变异性（GV）的影响使用连续葡萄糖监测。材料和方法本研究是对11名2型糖尿病门诊病人（7％<糖化血红蛋白<10％）接受低剂量二甲双胍单药治疗（500-1,000 mg）进行的。所有患者均接受了1,500 mg二甲双胍单药（HMET）或小剂量（750 mg）二甲双胍和linagliptin 5 mg（LMET +二肽基肽酶-4 [DPP4]）的联合治疗。在初始治疗> 4周后以及在过渡到其他治疗后再次通过连续葡萄糖监测评估GV。使用Wilcoxon秩和检验比较治疗之间的GV指标。结果在HMET与LMET + DPP4的连续葡萄糖监测得出的GV指标中，平均葡萄糖水平，标准差和平均葡萄糖波动幅度均无显着差异。尽管早餐前的血糖水平在各处理之间无显着差异（P = 0.248），但早餐后HMET曲线下餐后3小时的葡萄糖面积（> 160 mg / dL）明显大于LMET + DPP4（9,550） [2,075-11,395]与4,065 [1,950-8,895]; P = 0.041）。结论GMET和HMET与LMET + DPP4的比较表明，在接受低剂量二甲双胍单药治疗的2型糖尿病患者中，LMET + DPP4可能比HMET更大程度地降低早餐后GV。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号